
    
      Twenty patients with hidradenitis suppurativa will be enrolled and randomised to treatment
      with either botulinum toxin B or placebo (saline) in affected areas.

      Intervention and recording of data will be performed every three months. After three months,
      all patients will receive active substance. After six months, randomization will revealed.
      Patients with clinical improvement will be given the opportunity to continue treatment for
      additional six months.
    
  